Giorgio Minotti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5114121/publications.pdf

Version: 2024-02-01

135 papers	12,119 citations	66250 44 h-index	29333 108 g-index
145 all docs	145 docs citations	145 times ranked	14945 citing authors

#	Article	IF	Citations
1	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
2	Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 177-190.	1.2	12
3	Sodiumâ€“Glucose Cotransporter Inhibitors Reduce Mortality and Morbidity in Patients With Heart Failure: Evidence From a Meta-Analysis of Randomized Trials. American Journal of Therapeutics, 2022, 29, e199-e204.	0.5	6
4	Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Advances in Pharmacology, 2022, , .	1.2	5
5	From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction. JACC: CardioOncology, 2022, 4, 139-140.	1.7	7
6	Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatmentâ€“Related Early Diastolic Dysfunction. Journal of Pharmacology and Experimental Therapeutics, 2022, 381, 266-273.	1.3	1
7	The Reality of Pixantrone in Real Life. Acta Haematologica, 2021, 144, 244-245.	0.7	1
8	Safety and tolerability of a novel oral nutritional supplement in healthy volunteers. Clinical Nutrition, 2021, 40, 946-955.	2.3	4
9	Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological Appraisal. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 231-239.	1.3	5
10	Quo Vadis COVID? Lessons from a Focus Topic Issue of Chemotherapy. Chemotherapy, 2021, 66, 1-2.	0.8	0
11	Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life. Chemotherapy, 2021, 66, 47-52.	0.8	10
12	Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e74-e76.	1.4	8
13	Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection. Clinical Cancer Research, 2021, 27, 3809-3811.	3.2	10
14	Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases. Expert Review of Hematology, 2021, 14, 537-546.	1.0	17
15	Risk of Myocardial Infarction in Patients Treated With 5-Fluorouracil. JACC: CardioOncology, 2021, 3, 734-736.	1.7	0
16	In Â®Entresto we trust. Cardio-Oncology, 2020, 6, 25.	0.8	3
17	Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103074.	2.0	12
18	The cancer patient and cardiology. European Journal of Heart Failure, 2020, 22, 2290-2309.	2.9	62

#	Article	IF	Citations
19	Cardioâ€oncology care in the era of the coronavirus disease 2019 (COVIDâ€19) pandemic: An International Cardioâ€Oncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	157.7	29
20	Acute HeartÂFailure 29 Years After Treatment for Childhood Cancer. JACC: CardioOncology, 2020, 2, 316-319.	1.7	12
21	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Chemotherapy, 2020, 65, 35-41.	0.8	1
22	Efficacy and safety of low dose ponatinib in a case of Phâ€positive acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 187, e15-e17.	1.2	7
23	Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 197-205.	1.3	13
24	Cardiotoxicity of Targeted Cancer Drugs: Concerns, â€œThe Cart Before the Horse,â€•and Lessons from Trastuzumab. Current Cardiology Reports, 2019, 21, 33.	1.3	8
25	Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Seminars in Oncology, 2019, 46, 397-402.	0.8	16
26	Treatment specific toxicities: Hormones, antihormones, radiation therapy. Seminars in Oncology, 2019, 46, 414-420.	0.8	7
27	Helping the cardio-oncologist: from real life to guidelines. Seminars in Oncology, 2019, 46, 433-436.	0.8	1
28	Cardiovascular events in cancer survivors. Seminars in Oncology, 2019, 46, 426-432.	0.8	8
29	Cardio-oncological management of patients. Seminars in Oncology, 2019, 46, 408-413.	0.8	10
30	Old and new directions of Cardio-Oncology. Seminars in Oncology, 2019, 46, 395-396.	0.8	3
31	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. Hematological Oncology, 2018, 36, 624-632.	0.8	55
32	Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. Chemotherapy, 2018, 63, 55-63.	0.8	23
33	Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 323-331.	1.3	15
34	Isavuconazole: Case Report and Pharmacokinetic Considerations. Chemotherapy, 2018, 63, 253-256.	0.8	8
35	The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 518-527.	1.3	4
36	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert Opinion on Drug Safety, 2018, 17, 623-628.	1.0	10

#	ARTICLE	IF	CITATIONS
37	The International Cardioncology Societyâ€"ONE trial: Not all that glitters is for cardioncologists only. European Journal of Cancer, 2018, 97, 27-29.	1.3	3
38	Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 158-168.	1.3	10
39	Pixantrone: novel mode of action and clinical readouts. Expert Review of Hematology, 2018, 11, 587-596.	1.0	11
40	Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 263-270.	1.3	15
41	Early diagnosis of acute coronary syndrome. European Heart Journal, 2017, 38, 3049-3055.	1.0	50
42	Cancer drugs and QT prolongation: weighing risk against benefit. Expert Opinion on Drug Safety, 2017, 16, 1099-1102.	1.0	9
43	Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. Clinical Research in Cardiology, 2017, 106, 69-75.	1.5	25
44	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal of Heart Failure, 2017, 19, 9-42.	2.9	920
45	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. Annals of Hematology, 2017, 96, 549-558.	0.8	48
46	Do You Know Pixantrone?. Chemotherapy, 2017, 62, 192-193.	0.8	2
47	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in nonâ€Hodgkin lymphoma: a <scp>SIE</scp>,<scp> SIES</scp>, and <scp>GITMO</scp> consensus paper. European Journal of Haematology, 2016, 97, 554-561.	1.1	9
48	Drug-induced hepatotoxicity in cancer patients - implication for treatment. Expert Opinion on Drug Safety, 2016, 15, 1219-1238.	1.0	52
49	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 2016, 37, 2768-2801.	1.0	1,996
50	Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines. Chemical Research in Toxicology, 2016, 29, 1270-1278.	1.7	20
51	An Invitation from the Editors of Cardio-Oncology. Cardio-Oncology, 2015, 1, 2.	0.8	3
52	The Second Special Cardio-Oncology Issue of Progress in Pediatric Cardiology: Closing remarks and hopes for the future. Progress in Pediatric Cardiology, 2015, 39, 57.	0.2	0
53	The concomitant management of cancer therapy and cardiac therapy. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2727-2737.	1.4	43
54	Managing anthracycline-induced cardiotoxicity: beginning with the end in mind. Future Cardiology, 2015, 11, 363-366.	0.5	13

#	ARTICLE	IF	CITATIONS
55	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 433.	0.6	12
56	New frontiers in Cardio-Oncology. Progress in Pediatric Cardiology, 2014, 36, 1-2.	0.2	0
57	Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: An update of the evidence. Progress in Pediatric Cardiology, 2014, 36, 39-49.	0.2	34
58	Low Level Tumor Necrosis Factor-Alpha Protects Cardiomyocytes Against High Level Tumor Necrosis Factor-Alpha: Brief Insight into a Beneficial Paradox. Cardiovascular Toxicology, 2014, 14, 387-392.	1.1	7
59	What is cardiotoxicity?. Progress in Pediatric Cardiology, 2014, 36, 3-6.	0.2	3
60	Development of a Tumorâ€Specific Photoactivatable Doxorubicin Prodrug. Photochemistry and Photobiology, 2013, 89, 1009-1010.	1.3	2
61	Pharmacology at Work for Cardio-Oncology: Ranolazine to Treat Early Cardiotoxicity Induced by Antitumor Drugs. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 343-349.	1.3	44
62	The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 467-478.	1.3	50
63	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. II. Amrubicin Shows Metabolic Advantages over Doxorubicin and Epirubicin. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 474-483.	1.3	29
64	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. I. Amrubicin Accumulates to a Lower Level than Doxorubicin or Epirubicin. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 464-473.	1.3	11
65	Pharmacokinetics of Pegylated Liposomal Doxorubicin Administered by Intraoperative Hyperthermic Intraperitoneal Chemotherapy to Patients with Advanced Ovarian Cancer and Peritoneal Carcinomatosis. Drug Metabolism and Disposition, 2012, 40, 2365-2373.	1.7	18
66	Anthracycline cardiotoxicity. Expert Opinion on Drug Safety, 2012, 11, S21-S36.	1.0	161
67	Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. Autoimmunity Reviews, 2011, 10, 631-635.	2.5	50
68	Matters of the Heart: The Case of TNFÂ-Targeting Drugs. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2011, 11, 79-87.	3.4	3
69	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori, 2011, 97, 690-2.	0.6	15
70	Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment. Blood, 2011, 118, 4966-4966.	0.6	0
71	Managing cardiac risk factors in oncology clinical trials. Texas Heart Institute Journal, 2011, 38, 266-7.	0.1	5
72	Pharmacological Foundations of Cardio-Oncology. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 2-8.	1.3	81

#	ARTICLE	IF	CITATIONS
73	Iron Regulatory Proteins: From Molecular Mechanisms to Drug Development. Antioxidants and Redox Signaling, 2010, 13, 1593-1616.	2.5	103
74	Anthracycline Degradation in Cardiomyocytes: A Journey to Oxidative Survival. Chemical Research in Toxicology, 2010, 23, 6-10.	1.7	59
75	Doxorubicinolone Formation and Efflux: A Salvage Pathway against Epirubicin Accumulation in Human Heart. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 175-184.	1.3	21
76	4â€²-Epidoxorubicin To Re-explore Anthracycline Degradation in Cardiomyocytes. Chemical Research in Toxicology, 2009, 22, 978-983.	1.7	5
77	Beyond Poisons and Problems: Toxicology in Italy. Chemical Research in Toxicology, 2008, 21, 771-774.	1.7	1
78	Cardiotoxicity of Antitumor Drugs. Chemical Research in Toxicology, 2008, 21, 978-989.	1.7	143
79	Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 790-800.	1.3	35
80	Doxorubicin Degradation in Cardiomyocytes. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 408-419.	1.3	38
81	Anthracycline Cardiotoxicity. Topics in Current Chemistry, 2007, 283, 21-44.	4.0	26
82	In vitro modeling of the structureâ€“activity determinants of anthracycline cardiotoxicity. Cell Biology and Toxicology, 2007, 23, 49-62.	2.4	41
83	An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovascular Toxicology, 2007, 7, 80-85.	1.1	73
84	Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 2007, 7, 67-71.	1.1	107
85	The anthracyclines: When good things go bad. Cardiovascular Toxicology, 2007, 7, 53-55.	1.1	8
86	Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart. Journal of Biological Chemistry, 2006, 281, 10990-11001.	1.6	88
87	Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 424-433.	1.3	63
88	Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs. Drug Design Reviews Online, 2005, 2, 267-276.	0.7	0
89	Doxorubicin Paradoxically Protects Cardiomyocytes against Iron-mediated Toxicity. Journal of Biological Chemistry, 2004, 279, 13738-13745.	1.6	74
90	Oxidative Degradation of Cardiotoxic Anticancer Anthracyclines to Phthalic Acids. Journal of Biological Chemistry, 2004, 279, 5088-5099.	1.6	31

#	ARTICLE	IF	CITATIONS
91	Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews, 2004, 56, 185-229.	7.1	3,060
92	Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms. Methods in Enzymology, 2004, 378, 340-361.	0.4	101
93	Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications. Biochemical Pharmacology, 2003, 66, 989-998.	2.0	58
94	Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. British Journal of Pharmacology, 2003, 139, 641-651.	2.7	44
95	Cardiotoxic effects of anthracyclineâ€"taxane combinations. Expert Opinion on Drug Safety, 2003, 2, 59-71.	1.0	21
96	Anthracyclines. Cancer Chemotherapy and Biological Response Modifiers, 2003, , 29-40.	0.5	21
97	Anthracyclines. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 29-40.	0.5	5
98	Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation:Â Implications for Cardiotoxicity of Anticancer Anthracyclines. Chemical Research in Toxicology, 2002, 15, 1179-1189.	1.7	32
99	Nitric Oxide and Peroxynitrite Activate the Iron Regulatory Protein-1 of J774A.1 Macrophages by Direct Disassembly of the Feâ˘'S Cluster of Cytoplasmic Aconitaseâ€. Biochemistry, 2002, 41, 7435-7442.	1.2	62
100	The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage1,2 1Guest Editor: Mario Comporti 2This article is part of a series of reviews on â€œIron and Cellular Redox Status.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 32, 1237-1243.	1.3	160
101	Anthracyclines. Cancer Chemotherapy and Biological Response Modifiers, 2002, 20, 59-69.	0.5	2
102	Human Heart Cytosolic Reductases and Anthracycline Cardiotoxicity. IUBMB Life, 2001, 52, 83-88.	1.5	71
103	Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. British Journal of Pharmacology, 2001, 134, 1271-1278.	2.7	32
104	Anthracycline Metabolism and Toxicity in Human Myocardium: Comparisons between Doxorubicin, Epirubicin, and a Novel Disaccharide Analogue with a Reduced Level of Formation and [4Fe-4S] Reactivity of Its Secondary Alcohol Metabolite. Chemical Research in Toxicology, 2000, 13, 1336-1341.	1.7	68
105	Doxorubicin Metabolism and Toxicity in Human Myocardium:Â Role of Cytoplasmic Deglycosidation and Carbonyl Reduction. Chemical Research in Toxicology, 2000, 13, 414-420.	1.7	147
106	Biochemical and Pharmacological Properties of Coenzyme Q Analogs. Modern Nutrition, 2000, , 151-160.	0.1	0
107	Role of iron in anthracycline cardiotoxicity: new tunes for an old song?. FASEB Journal, 1999, 13, 199-212.	0.2	183
108	Effect of Reactive Oxygen Species on Iron Regulatory Protein Activitya. Annals of the New York Academy of Sciences, 1998, 851, 179-186.	1.8	28

#	ARTICLE	IF	CITATIONS
109	Antioxidant Properties of 2,3-Dimethoxy-5-methyl- 6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone). Chemical Research in Toxicology, 1998, 11, 54-63.	1.7	107
110	The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory proteinâ€1 in cytosolic fractions from human myocardium. FASEB Journal, 1998, 12, 541-552.	0.2	147
111	Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Molecular Brain Research, 1997, 50, 267-276.	2.5	53
112	In Vivo Formation of 8-Epi-Prostaglandin F _{2Î±} Is Increased in Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3230-3235.	1.1	356
113	Superoxide and hydrogen peroxideâ€dependent inhibition of iron regulatory protein activity: a protective stratagem against oxidative injury. FASEB Journal, 1996, 10, 1326-1335.	0.2	128
114	Sources and role of iron in lipid peroxidation. Chemical Research in Toxicology, 1993, 6, 134-146.	1.7	146
115	The role of an endogenous nonheme iron in microsomal redox reactions. Archives of Biochemistry and Biophysics, 1992, 297, 189-198.	1.4	31
116	Redox cycling of iron and lipid peroxidation. Lipids, 1992, 27, 219-226.	0.7	247
117	Possible Sources of Iron for Lipid Peroxidation. Free Radical Research Communications, 1991, 12, 99-106.	1.8	14
118	Microsomal iron-dependent NADPH oxidation: Evidence for the involvement of membrane-bound nonheme iron in NADPH oxidation by rat heart microsomes. Archives of Biochemistry and Biophysics, 1990, 282, 270-274.	1.4	12
119	NADPH- and adriamycin-dependent microsomal release of iron and lipid peroxidation. Archives of Biochemistry and Biophysics, 1990, 277, 268-276.	1.4	51
120	Reactions of Adriamycin with Microsomal Iron and Lipids. Free Radical Research Communications, 1989, 7, 143-148.	1.8	11
121	The role of iron in oxygen radical mediated lipid peroxidation. Chemico-Biological Interactions, 1989, 71, 1-19.	1.7	175
122	tert-Butyl hydroperoxide-dependent microsomal release of iron and lipid peroxidation. Archives of Biochemistry and Biophysics, 1989, 273, 137-143.	1.4	25
123	tert-Butyl hydroperoxide-dependent microsomal release of iron and lipid peroxidation. Archives of Biochemistry and Biophysics, 1989, 273, 144-147.	1.4	25
124	Adriamycin-dependent release of iron from microsomal membranes. Archives of Biochemistry and Biophysics, 1989, 268, 398-403.	1.4	51
125	Metals and Membrane Lipid Damage by Oxy-Radicals. Annals of the New York Academy of Sciences, 1988, 551, 34-44.	1.8	18
126	Superoxide-dependent redox cycling of citrate-Fe3+: Evidence for a superoxide dismutaselike activity. Archives of Biochemistry and Biophysics, 1987, 253, 257-267.	1.4	31

#	ARTICLE	IF	CITATIONS
127	An investigation into thee mechanism of citrateî—¸FE2+-dependent lipid peroxidation. Free Radical Biology and Medicine, 1987, 3, 379-387.	1.3	217
128	The role of iron in the initiation of lipid peroxidation. Chemistry and Physics of Lipids, 1987, 44, 191-208.	1.5	247
129	Cytochrome P-450 deficiency and resistance to t-butyl hydroperoxide of hepatoma microsomal lipid peroxidation. Lipids and Lipid Metabolism, 1986, 876, 220-225.	2.6	39
130	O2â˜’dependent lipid peroxidation does not affect the molecular order in hepatoma microsomes. FEBS Letters, 1986, 198, 301-306.	1.3	13
131	Restoration of hydroperoxide-dependent lipid peroxidation by 3-methylcholanthrene induction ofcytochrome P-448 in hepatoma microsomes. FEBS Letters, 1986, 209, 305-310.	1.3	4
132	Membrane Alterations in Cancer Cells:.. Annals of the New York Academy of Sciences, 1986, 488, 468-480.	1.8	34
133	Membrane Alterations in Cancer Cells:.. Annals of the New York Academy of Sciences, 1986, 488, 468-480.	1.8	52
134	Superoxide-dependent lipid peroxidation and vitamin E content of microsomes from hepatomas with different growth rates. Archives of Biochemistry and Biophysics, 1985, 238, 588-595.	1.4	39
135	Lipid Composition, Physical State, and Lipid Peroxidation of Tumor Membranes. Toxicologic Pathology, 1984, 12, 324-330.	0.9	10